Slowdown: US FDA’s 2025 Novel Approvals Are On Below-Average Pace

 
• By Bridget Silverman
  
At the mid-point of 2025, FDA and industry are facing a strenuous hike if novel approval numbers are to regain past year levels. (Shutterstock)

More from Approvals

More from Product Reviews